Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.05)
# 470
Out of 5,090 analysts
77
Total ratings
54.93%
Success rate
12%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $68 → $80 | $66.62 | +20.08% | 5 | Nov 26, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $29.36 | +19.21% | 3 | Nov 19, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $577.30 | +10.86% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $102.52 | -9.29% | 12 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $76 → $88 | $89.65 | -1.84% | 3 | Oct 28, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $45.02 | -2.27% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $10.93 | +37.24% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $31.97 | +56.40% | 1 | Oct 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $718.36 | +13.04% | 8 | Aug 11, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $12.79 | -14.00% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $199 | $181.30 | +9.76% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $21.69 | +15.26% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,010.31 | +2.74% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $226.08 | -4.02% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $26.03 | +22.94% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $23.59 | +111.95% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.22 | +4,326.23% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $10.36 | +44.79% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $18.09 | +99.00% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $65.67 | +6.59% | 4 | May 29, 2024 |
Kymera Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $68 → $80
Current: $66.62
Upside: +20.08%
Terns Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $29.36
Upside: +19.21%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $577.30
Upside: +10.86%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $102.52
Upside: -9.29%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76 → $88
Current: $89.65
Upside: -1.84%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $45.02
Upside: -2.27%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $10.93
Upside: +37.24%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $31.97
Upside: +56.40%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $718.36
Upside: +13.04%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $12.79
Upside: -14.00%
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $181.30
Upside: +9.76%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $21.69
Upside: +15.26%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,010.31
Upside: +2.74%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $226.08
Upside: -4.02%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.03
Upside: +22.94%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $23.59
Upside: +111.95%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.22
Upside: +4,326.23%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $10.36
Upside: +44.79%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $18.09
Upside: +99.00%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $65.67
Upside: +6.59%